IL309195A - Converted pyrrolo[2,3-D]pyrimidines, their preparation and therapeutic application - Google Patents
Converted pyrrolo[2,3-D]pyrimidines, their preparation and therapeutic applicationInfo
- Publication number
- IL309195A IL309195A IL309195A IL30919523A IL309195A IL 309195 A IL309195 A IL 309195A IL 309195 A IL309195 A IL 309195A IL 30919523 A IL30919523 A IL 30919523A IL 309195 A IL309195 A IL 309195A
- Authority
- IL
- Israel
- Prior art keywords
- pyrimidines
- preparation
- therapeutic application
- substituted pyrrolo
- pyrrolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21315095.6A EP4105218A1 (en) | 2021-06-15 | 2021-06-15 | Substituted pyrrolo[2,3-d] pyrimidines, their preparation and their therapeutic application |
| EP22315117 | 2022-06-02 | ||
| PCT/EP2022/066231 WO2022263472A1 (en) | 2021-06-15 | 2022-06-14 | Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL309195A true IL309195A (en) | 2024-02-01 |
Family
ID=82214141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL309195A IL309195A (en) | 2021-06-15 | 2022-06-14 | Converted pyrrolo[2,3-D]pyrimidines, their preparation and therapeutic application |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240383901A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4355748B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7886355B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240021910A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022294022A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023025042A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3223786A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024000083A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL309195A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023015016A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022263472A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL330303A (en) * | 2023-12-27 | 2026-08-01 | Sanofi | Modified pyrrolo[2,3-d]pyrimidins, their preparation and therapeutic applications |
| KR20250163526A (ko) | 2024-05-14 | 2025-11-21 | 김성우 | 음전하 증폭장치가 장착된 어싱용 발판 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI398252B (zh) * | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| FR2988722B1 (fr) | 2012-04-03 | 2014-05-09 | Sanofi Sa | Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques |
| CN106146515B (zh) | 2015-04-17 | 2020-09-04 | 常州隆赛医药科技有限公司 | 新型激酶抑制剂的制备及应用 |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| CN108934162A (zh) | 2015-12-16 | 2018-12-04 | 南方研究所 | 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法 |
| EP3587422A4 (en) | 2017-02-22 | 2020-05-06 | Daegu-Gyeongbuk Medical Innovation Foundation | PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE |
| EP3873471B1 (en) | 2018-10-31 | 2025-12-31 | Merck Sharp & Dohme LLC | N-HETEROARYL INDAZOLE DERIVATIVES AS LRRK2 INHIBITORS: PHARMACEUTICAL COMPOSITIONS AND THEIR USES |
| EP3915985A4 (en) | 2019-01-18 | 2022-09-28 | Voronoi Co., Ltd. | PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES |
-
2022
- 2022-06-14 MX MX2023015016A patent/MX2023015016A/es unknown
- 2022-06-14 IL IL309195A patent/IL309195A/en unknown
- 2022-06-14 WO PCT/EP2022/066231 patent/WO2022263472A1/en not_active Ceased
- 2022-06-14 US US18/569,790 patent/US20240383901A1/en active Pending
- 2022-06-14 BR BR112023025042A patent/BR112023025042A2/pt unknown
- 2022-06-14 EP EP22733628.6A patent/EP4355748B1/en active Active
- 2022-06-14 JP JP2023577130A patent/JP7886355B2/ja active Active
- 2022-06-14 KR KR1020247001337A patent/KR20240021910A/ko active Pending
- 2022-06-14 CA CA3223786A patent/CA3223786A1/en active Pending
- 2022-06-14 AU AU2022294022A patent/AU2022294022A1/en active Pending
-
2024
- 2024-01-05 CO CONC2024/0000083A patent/CO2024000083A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024525150A (ja) | 2024-07-10 |
| JP7886355B2 (ja) | 2026-07-07 |
| WO2022263472A1 (en) | 2022-12-22 |
| KR20240021910A (ko) | 2024-02-19 |
| CO2024000083A2 (es) | 2024-04-08 |
| BR112023025042A2 (pt) | 2024-02-27 |
| US20240383901A1 (en) | 2024-11-21 |
| MX2023015016A (es) | 2024-05-31 |
| EP4355748A1 (en) | 2024-04-24 |
| AU2022294022A1 (en) | 2024-02-01 |
| EP4355748C0 (en) | 2026-05-13 |
| CA3223786A1 (en) | 2022-12-22 |
| EP4355748B1 (en) | 2026-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL325562A (en) | Crystal structure of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, methods of preparation and uses thereof | |
| IL288872B1 (en) | IMIDAZO[1,5-c]PYRIMIDIN-5-AMINE PERI-CONDENSED DERIVATIVES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USES IN CANCER TREATMENT | |
| MX2009002995A (es) | Derivados de pirazolo-[1,5-a]-pirimidina y su uso terapeutico. | |
| IL289164A (en) | The history of imidazo[2,1-a)pyridinyl and their use in the treatment of diseases | |
| EP3250208A4 (en) | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy | |
| IL180757A0 (en) | Imidazo[4,5-d] pyrimidines, their uses and methods of preparation | |
| PT3800189T (pt) | Preparação de (s)-n-(5-((r)-2-(2,5- difluoropenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroxipirrolidina-1-carboxamida | |
| CA3261509A1 (en) | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | |
| IL187900A0 (en) | Derivatives of pyrido[2,3-d] pyrimidine, the preparation thereof, and the therapeutic application of the same | |
| IL268923A (en) | History of alicyclic-converted pyrazolo[5,1-a]pyrimidine pharmacological activity | |
| ZA202210537B (en) | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2a receptor and adenosine 2b receptor antagonist | |
| IL206673A0 (en) | Imidazo[1,2-a]pyridine-2-carboxamide derivatives, their preparation and their therapeutic application | |
| EP3750891A4 (en) | PYRAZOLO [1,5-A] [1,3,5] TRIAZINE-2-AMINE DERIVATIVE, METHOD OF PREPARATION AND MEDICAL USE | |
| IL318390A (en) | Imidazopyridine compounds, their preparation and therapeutic uses | |
| ZA201209071B (en) | 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof | |
| ZA201000581B (en) | 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof | |
| IL287887A (en) | Synthesis of labeled imidazo[2,1-a]pyrimidines | |
| HK40110078A (en) | Substituted pyrrolo[2,3-d]pyrimidines, their preparation and their therapeutic application | |
| IL326261A (en) | IMIDAZO[4,5-D]PYRIDAZINE COMPOUNDS AND THEIR CONJUGATES, METHODS OF PREPARATION AND THEIR THERAPEUTIC APPLICATIONS | |
| IL278935B2 (en) | Piazolo[e-3,4]pyrimidine compounds are being modified for use in cancer treatment | |
| HK40097825A (en) | Imidazo[1,2-a]pyridine compounds and their use in therapy | |
| HK40115318A (en) | 7h-pyrrolo[2,3-d]pyrimidines and preparation as dyrk1a inhibitors | |
| HK40087730A (en) | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2a receptor and adenosine 2b receptor antagonist | |
| HK40090671A (en) | Pyrazolo[1,5-a]pyrimidine derivatives having multimodal activity against pain | |
| HK40073506A (en) | Imidazo[1,2-a]pyridinyl derivatives and their use in the treatment of disease |